 <h1>Noroxin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>norfloxacin</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about norfloxacin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Noroxin.</p><p><i>Applies to norfloxacin: oral tablet</i></p><h3>General</h3><p>This drug was generally well tolerated and side effects were mild.  Side effects were reported in 6.5% of subjects receiving single doses and 3.6% of subjects receiving multiple doses.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, abdominal cramping</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal pain, anal/rectal pain, constipation, diarrhea, dry mouth, dyspepsia/heartburn, flatulence, loose stools, vomiting, abdominal swelling, mouth ulcer, pruritus ani</p><p><b>Rare</b> (0.01% to 0.1%): Pseudomembranous colitis, pancreatitis</p><p><b>Postmarketing reports</b>: Stomatitis</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Intestinal perforation<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.</p><p></p><p>Pseudomembranous colitis and pancreatitis have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Cases of sensory or sensorimotor axonal polyneuropathy (affecting small and/or large axons) resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported.</p><p></p><p>Seizures reported in association with this drug have occurred, generally in older patients.  A patient with myasthenia gravis had her condition deteriorate during 2 different courses of this drug.</p><p></p><p>Paresthesia, polyneuropathy (including Guillain-Barre syndrome), tinnitus, and exacerbation of myasthenia gravis have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Tingling of the fingers, somnolence/drowsiness, bitter taste</p><p><b>Rare</b> (less than 0.1%): Peripheral sensory neuropathy/sensory axonal polyneuropathy, peripheral sensory motor neuropathy/sensorimotor axonal polyneuropathy, paresthesia, polyneuropathy, Guillain-Barre syndrome, seizures, tinnitus, exacerbation of myasthenia gravis</p><p><b>Frequency not reported</b>: Dysesthesia, altered taste</p><p><b>Postmarketing reports</b>: Generalized seizures, convulsions, myoclonus, tremors, peripheral neuropathy (may be irreversible), ataxia, hypoesthesia, hearing loss, dysgeusia, hypertonia, dysarthria, dysphasia</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Dysphasia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergies/allergic reactions</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic/anaphylactoid reactions</p><p><b>Postmarketing reports</b>: Hypersensitivity reactions (including anaphylactoid reactions, anaphylaxis, angioedema, dyspnea, vasculitis, urticaria, arthritis, arthralgia, myalgia, interstitial nephritis, DRESS syndrome)<sup>[Ref]</sup></p><h3>Renal</h3><p>Interstitial nephritis has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Interstitial nephritis</p><p><b>Frequency not reported</b>: Decreased renal function, nephrotic syndrome (which has occurred in patients treated with high doses), increased BUN/serum urea, increased serum creatinine</p><p><b>Postmarketing reports</b>: Renal failure</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Renal calculi<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST, cholestatic hepatitis, hepatitis</p><p><b>Frequency not reported</b>: Eosinophilic necrotizing granulomatous hepatitis</p><p><b>Postmarketing reports</b>: Jaundice (including cholestatic jaundice), elevated liver function tests, hepatic failure (including fatal cases)</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Hepatic necrosis<sup>[Ref]</sup></p><p>Hepatitis has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Eosinophilia, decreased WBC, decreased neutrophil count, decreased platelet count</p><p><b>Uncommon</b> (0.1% to 1%): Decreased hematocrit, decreased hemoglobin, increased eosinophils, leukopenia, neutropenia, thrombocytopenia, prothrombin time prolongation</p><p><b>Rare</b> (0.01% to 0.1%): Hemolytic anemia</p><p><b>Postmarketing reports</b>: Agranulocytosis</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Agranulocytosis, prothrombin time prolongation<sup>[Ref]</sup></p><p>Eosinophilia was reported in 7.5% of 1 study population.  Leukopenia and neutropenia have been reported in up to 1% of patients.  Hemolytic anemia has sometimes been associated with glucose-6-phosphate dehydrogenase deficiency.</p><p></p><p>Leukopenia, neutropenia, hemolytic anemia, prothrombin time prolongation, and thrombocytopenia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Quinolones, including this drug, have been associated with ruptures of the shoulder, hand, Achilles, and other tendons resulting in disability or requiring surgical repair.  Elderly patients and patients concomitantly using corticosteroids may be at increased risk.</p><p></p><p>Renal transplant patients have an increased risk of Achilles tendinitis and rupture over the general population.  Quinolone use has been shown to increase that risk further in this population (12% in quinolone-treated patients versus 7% in patients not treated).</p><p></p><p>There have been 23 reports of tendinitis submitted to the Australian Adverse Drug Reactions Committee (ADRAC) between 2006 and 2008, including reports of Achilles tendonitis, tendon rupture, and tendon pain and swelling.  The reports were primarily in male patients (15 cases) older than 56 years who used ciprofloxacin for 2 to 14 days.  In 19 of the reported cases, a fluoroquinolone (generally ciprofloxacin) was the primary suspect; however, details of concomitant serious medical conditions were not documented in most of the reports.</p><p></p><p>Tendinitis and tendon rupture have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rhabdomyolysis</p><p><b>Uncommon</b> (0.1% to 1%): Bursitis, back pain</p><p><b>Rare</b> (0.01% to 0.1%): Tendinitis, tendosynovitis, myalgia/muscle pains, joint pains, joint inflammation</p><p><b>Very rare</b> (less than 0.01%): Tendon rupture (e.g., Achilles tendon)</p><p><b>Frequency not reported</b>: Bilateral arthritis of the ankles</p><p><b>Postmarketing reports</b>: Elevated creatine kinase, muscle spasms<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, elevated alkaline phosphatase</p><p><b>Uncommon</b> (0.1% to 1%): Fever, fatigue, chest pain, foot or hand swelling, chills, edema</p><p><b>Rare</b> (0.01% to 0.1%): Tiredness</p><p><b>Frequency not reported</b>: Weakness, elevated LDH</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Elevated serum triglycerides, elevated serum cholesterol, elevated serum potassium<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, pruritus, hyperhidrosis, erythema, urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Petechiae, hemorrhagic bullae/papules with vasculitis, skin reactions, exfoliative dermatitis, toxic epidermal necrolysis (Lyell's syndrome), erythema multiforme, Stevens-Johnson syndrome, photosensitivity, angioedema</p><p><b>Frequency not reported</b>: Systemic contact dermatitis</p><p><b>Postmarketing reports</b>: Leukocytoclastic vasculitis, drug rash with eosinophilia and systemic symptoms (DRESS syndrome), photosensitivity/phototoxicity reactions, periorbital erythema</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Erythema nodosum, photosensitivity (phototoxic reactions, photosensitization with vesiculation, redness, swelling, discoloration)<sup>[Ref]</sup></p><p>Rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, pruritus, and exfoliative dermatitis have also been reported during postmarketing experience.  Rash has been reported as the most common side effect during postmarketing experience.</p><p></p><p>A 70-year-old male developed systemic contact dermatitis, an itchy papulopustular eruption from the thighs to the abdomen, after 3 days of therapy with this drug.  The patient was treated with prednisone for 15 days.  A patch test 1 month later resulted in a reaction to quinolone mix.</p><p></p><p>Photosensitivity has been reported in patients extensively exposed to sunlight or sunbeds during ongoing therapy with quinolone-like agents.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Crystalluria has occurred in patients taking doses greater than 1200 mg/day and whose urine pH was 7 to 7.8.</p><p></p><p>Crystalluria and vaginal candidiasis have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased urine protein</p><p><b>Uncommon</b> (0.1% to 1%): Dysmenorrhea, renal colic, crystalluria</p><p><b>Rare</b> (0.01% to 0.1%): Vaginal candidiasis</p><p><b>Frequency not reported</b>: Glycosuria, vaginal swelling</p><p><b>Postmarketing reports</b>: Proteinuria</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Crystalluria, albuminuria, candiduria, cylindruria, hematuria, vaginal candidiasis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction, palpitation</p><p><b>Frequency not reported</b>: Tachycardia, ECG QT prolonged, cardiovascular collapse</p><p><b>Postmarketing reports</b>: Prolonged QTc interval, ventricular arrhythmia (including torsade de pointes)</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Postural hypotension<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Blurred vision</p><p><b>Rare</b> (0.01% to 0.1%): Visual disturbance, increased lacrimation</p><p><b>Postmarketing reports</b>: Diplopia, uveitis, nystagmus, conjunctivitis, eye pain/irritation, hemophthalmia</p><p></p><p>Quinolones:</p><p>-Postmarketing reports: Nystagmus, visual disturbances<sup>[Ref]</sup></p><p>Visual disturbances have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p><p><b>Rare</b> (0.01% to 0.1%): Loss of appetite</p><p><b>Postmarketing reports</b>: Dysglycemia</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Acidosis</p><p>-Postmarketing reports: Symptomatic hypoglycemia, elevated blood glucose<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Quinolones:</p><p>-Frequency not reported: Hiccough<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Anxiety, depression, insomnia, sleep disturbances</p><p><b>Rare</b> (0.01% to 0.1%): Mood changes, nervousness, irritability, euphoria, disorientation, hallucinations, confusion, psychic disturbances, psychotic reactions</p><p></p><p>Quinolones:</p><p>-Frequency not reported: Manic reactions<sup>[Ref]</sup></p><p>Psychic disturbances (including psychotic reactions) and confusion have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p id="ref_1">1. Wolfson JS, Hooper DC "Norfloxacin: a new targeted fluoroquinolone antimicrobial agent." Ann Intern Med 108 (1988): 238-51</p><p id="ref_2">2. Walker RC, Wright AJ "The quinolones." Mayo Clin Proc 62 (1987): 1007-12</p><p id="ref_3">3. "Product Information. Noroxin (norfloxacin)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_4">4. Sabbour MS, El Bokl MA, Osman LM "Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI)." Infection 12 (1984): 377-80</p><p id="ref_5">5. "Norfloxacin (noroxin)." Med Lett Drugs Ther 29 (1987): 25-7</p><p id="ref_6">6. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_7">7. Anonymous. "Prevention of bacterial infection in neutropenic patients with hematologic malignancies." Ann Intern Med 115 (1991): 7-12</p><p id="ref_8">8. The Urinary Tract Infection Study Group "Coordinated mulicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infection." J Infect Dis 155 (1987): 170-7</p><p id="ref_9">9. Ehrenpreis ED, Lievens MW, Craig RM "Clostridium difficile-associated diarrhea after norfloxacin." J Clin Gastroenterol 12 (1990): 188-9</p><p id="ref_10">10. Waites KB, Canupp KC, DeVivo MJ "Efficacy and tolerance of norfloxacin in treatment of complicated urinary tract infection in outpatients with neurogenic bladder secondary to spinal cord injury." Urology 38 (1991): 589-96</p><p id="ref_11">11. Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988): 169-70</p><p id="ref_12">12. Rauser EH, Ariano RE, Anderson BA "Exacerbation of myasthenia gravis by norfloxacin." DICP 24 (1990): 207-8</p><p id="ref_13">13. Ferguson J, Johnson BE "Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4-quinolone broad-spectrum antibiotic." Br J Dermatol 128 (1993): 285-95</p><p id="ref_14">14. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7</p><p id="ref_15">15. Alonso MD, Martin JA, Quirce S, Davila I, Lezaun A, Sanchez Cano M "Fixed eruption caused by ciprofloxacin with cross-sensitivity to norfloxacin." Allergy 48 (1993): 296-7</p><p id="ref_16">16. Sahin MT,  Ozturkcan S,  Inanir I,  Filiz EE "Norfloxacin-induced toxic epidermal necrolysis." Ann Pharmacother 39 (2005): 768-70</p><p id="ref_17">17. Bjornsson E, Olsson R, Remotti H "Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis." Am J Gastroenterol 95 (2000): 3662-4</p><p id="ref_18">18. Shelley ED, Shelley WB "The subcorneal pustular drug eruption: an example induced by norfloxacin." Cutis 42 (1988): 24-7</p><p id="ref_19">19. Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986): 272</p><p id="ref_20">20. Hanson B, Dhondt A, Depierreux M, Lustman F "Nephrotic syndrome after norfloxacin." Nephron 74 (1996): 446</p><p id="ref_21">21. Hestin D, Hanesse B, Frimat L, Renaudin JM, Netter P, Kessler M "Norfloxacin-induced nephrotic syndrome." Lancet 345 (1995): 732-3</p><p id="ref_22">22. Lucena MI, Andrade RJ, SanchezMartinez H, PerezSerrano JM, GomezOutes A "Norfloxacin-induced cholestatic jaundice." Am J Gastroenterol 93 (1998): 2309-11</p><p id="ref_23">23. Davoren P, Mainstone K "Norfloxacin-induced hepatitis." Med J Aust 159 (1993): 423,</p><p id="ref_24">24. RomeroGomez M, Garcia ES, Fernandez MC "Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis." Am J Gastroenterol 94 (1999): 2324-5</p><p id="ref_25">25. Lopez-Navidad A, Domingo P, Cadafalch J, Farrerons J "Norfloxacin-induced hepatotoxicity." J Hepatol 11 (1990): 277-8</p><p id="ref_26">26. Patoia L, Guerciolini R, Menichetti F, Bucaneve G, Del Favero A "Norfloxacin and neutropenia." Ann Intern Med 107 (1987): 788-9</p><p id="ref_27">27. Kaplan DS "Norfloxacin and protime elevation." Am J Gastroenterol 85 (1990): 901</p><p id="ref_28">28. Mofredj A,  Boudjema H,  Cadranel JF "Norfloxacin-induced eosinophilia in a cirrhotic patient." Ann Pharmacother 36 (2002): 1107-8</p><p id="ref_29">29. Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994): 736-7</p><p id="ref_30">30. Jeandel C, Manciaux MA, Bannwarth B, et al "Arthritis induced by norfloxacin." J Rheumatol 16 (1989): 560-1</p><p id="ref_31">31. Guis S,  Jouglard J,  Kozak-Ribbens G, et al. "Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment." J Rheumatol 28 (2001): 1405-6</p><p id="ref_32">32. Khaliq Y,  Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410</p><p id="ref_33">33. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA "Australian Adverse Drug Reactions Bulletin. Available from: URL: http://www.tga.gov.au/adr/aadrb/aadr0810.htm."   ([2008 Oct]):</p><p id="ref_34">34. Terry JB "Norfloxacin induced arthralgia." J Rheumatol 22 (1995): 793-4</p><p id="ref_35">35. Silvestre JF, Alfonso R, Moragon M, Ramon R, Botella R "Systemic contact dermatitis due to norfloxacin with a positive patch test to quinoline mix." Contact Dermatitis 39 (1998): 83</p><h2>More about Noroxin (norfloxacin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>2 Reviews</li>
<li>Drug class: quinolones</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Campylobacter Gastroenteritis</li>
<li>Gonococcal Infection, Uncomplicated</li>
<li>Bladder Infection</li>
<li>Epididymitis, Non-Specific</li>
<li data-more-config-id="list-data-resources-conditions">... +7 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>